CompletedPhase 1NCT04018599

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Studying Juvenile idiopathic arthritis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fresenius Kabi SwissBioSim GmbH
Principal Investigator
Radmila Kanceva, MD, PhD
Fresenius Kabi SwissBioSim GmbH
Intervention
40 mg MSB11022(drug)
Enrollment
216 enrolled
Eligibility
18-55 years · All sexes
Timeline
2019 – 2020

Study locations (2)

Collaborators

PRA Health Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04018599 on ClinicalTrials.gov

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile idiopathic arthritis →

← Back to all trials